查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
卵巢癌症治疗药的全球市场 - 产业规模，占有率，趋势，机会，预测:各类药物，各肿瘤类型，各流通管道，各地区(2017年～2027年)
市场调查报告书
商品编码
1152252

卵巢癌症治疗药的全球市场 - 产业规模，占有率，趋势，机会，预测:各类药物，各肿瘤类型，各流通管道，各地区(2017年～2027年)

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class, By Tumor Type, By Distribution Channel, By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球卵巢癌症治疗药的市场规模，在预测期间内的2023年～2027年预计达成惊人的成长。

卵巢癌症治疗药的市场，由于近几年的卵巢癌症患者数增加而在非常有利的情况下成长，在不久的将来，预计在已开发国家中大幅成长。还有高龄女性人口率的上升，推动在预测期间内的全球卵巢癌症治疗药市场。此外，市场企业和各种研究机关，对卵巢癌治疗药的开发的研究开发活动活性化。

本报告提供全球卵巢癌症治疗药市场相关调查分析，各市场区隔、各地区的市场规模、占有率预测，市场动态，企业简介等系统性资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 COVID-19对全球卵巢癌症治疗药市场的影响

第4章 VOC(客户的迴响)

第5章 临床试验分析

第6章 专利分析

第7章 全球卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物(烷化剂，有丝分裂抑制剂，抗风湿剂，抗干癣剂，VEGF/VEGFR抑制剂，PARP抑制剂，抗肿瘤剂，其他)
    • 各肿瘤类型(表皮性卵巢癌症，卵巢低恶性度肿瘤，生殖细胞瘤瘤，性绳索间品质肿瘤)
    • 各流通管道(院内药局，零售药局，线上药局)
    • 各企业(2021年)
    • 各地区
  • 市场地图

第8章 北美的卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物
    • 各肿瘤类型
    • 各流通管道
    • 各国
  • 北美:各国分析
    • 美国
    • 墨西哥
    • 加拿大

第9章 欧洲的卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物
    • 各肿瘤类型
    • 各流通管道
    • 各国
  • 欧洲:各国分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第10章 亚太地区的卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物
    • 各肿瘤类型
    • 各流通管道
    • 各国
  • 亚太地区:各国分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第11章 南美的卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物
    • 各肿瘤类型
    • 各流通管道
    • 各国
  • 南美:各国分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第12章 中东、非洲的卵巢癌症治疗药市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各类药物
    • 各肿瘤类型
    • 各流通管道
    • 各国
  • MEA:各国分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第13章 市场动态

  • 促进因素
  • 课题

第14章 市场趋势与开发

第15章 竞争情形

  • AstraZeneca, Plc.
  • GlaxoSmithKline, Plc.
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Novartis AG

第16章 策略性建议

简介目录
Product Code: 12865

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027. Ovarian Cancer is one of the most severe and common cancer that affects the women these days. The ovaries in this malignancy undergo irregular cell proliferation, which can invade or negatively impact other body parts like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. The early stages of ovarian cancer are accompanied by a few indistinct symptoms that become more obvious as the malignancy progresses. These signs include bloating, pelvic pain, abdominal swell, and appetite loss. Ovarian Cancer risk is higher in women who have ovulated more frequently throughout their life, which can also include women who have never given birth and those who started ovulating at a young age. According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer. 50% of women who carry BRCA1 or BRCA2 gene mutations will get breast or ovarian cancer. The most frequent type of ovarian cancer, accounting for 95% of occurrences worldwide, is ovarian carcinoma.

Growing Prevalence of Ovarian Cancer

The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases. The American Cancer Society reports that in 2016, there were approximately 22,280 new instances of ovarian cancer diagnosed, resulting in 14,240 fatalities in the United States. Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all fatalities attributable to cancer in 2016, according to statistics from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. There will be 23,820 new cases of ovarian cancer recorded in 2020, and the American Cancer Society believes that 1 in 75 women will get ovarian cancer during their lifetimes, with a 1 in 100 risks that she will pass away from it. As of 2017, 1,580 new ovarian cancer cases are anticipated to have been detected, making about 2.5% of all new cancer cases in the nation, according to the Australian Government's Cancer Australia. 1,047 fatalities are anticipated because of this in 2017. Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.

Increasing Elderly Female Population

The increase in the percentage of the elderly female population is expected to boost the global ovarian cancer drugs market during the forecast period. As the population of old females increases, they are projected to be suffering from more gynecological problems. For instance, according to the World Population Prospects, there were about 9.5% females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases or cancer. Ovarian cancer prevalence is often low in women under the age of 40. Most of the ovarian cancer cases are observed among women 60 years of age and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of those cases being identified in women 65 years of age and older, according to Cancer Research UK.

Increasing Research & Development Activities to Develop Ovarian Cancer Drugs

The growing prevalence of ovarian cancer has made the companies operating in the market along with different research organizations to increase their research & development activities in order to develop a potential drug treatment for ovarian cancer. Companies in the pharmaceutical business are increasingly coming up with novel drug combinations to treat ovarian cancer. To treat complex medical diseases, combination medications combine two or more active pharmaceutical ingredients (APIs) into a single dosage form. To lower manufacturing costs, boost compliance and efficiency, enhance medication concordance, increase profitability, and lessen side effects, pharmaceutical companies in the ovarian cancer medications market are investing in the research and development of novel products such as combination drugs. For instance, Roche's well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is a combination drug approved by the FDA that contains ingredients like carboplatin and paclitaxel.

Market Segmentation

The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution, by region. Based on by drug class, the market can be fragmented into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, antineoplastics and others. Based on tumor type, the market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor. Based on distribution channel, the market can be fragmented into hospital pharmacies, retail pharmacies, online pharmacies. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States held the biggest market in North America region and is expected to be a lucrative market in the forecast period as the government is investing in research for new drugs for the easy detection of ovarian cancer for the affected people.

Market Players

AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are some of the leading players operating in the global ovarian cancer drugs market.

Report Scope:

In this report, global ovarian cancer drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Drug Class:

  • Alkylating Agents
  • Mitotic Inhibitors
  • Antirheumatics
  • Antipsoriatics
  • VEGF/VEGFR Inhibitors
  • PARP Inhibitors
  • Antineoplastics
  • Others

Ovarian Cancer Drugs Market, By Tumor Type:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumor
  • Germ Cell Tumor
  • Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Ovarian Cancer Drugs Market

4. Voice of Customer

5. Clinical Trial Analysis

6. Patent Analysis

7. Global Ovarian Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others)
    • 7.2.2. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Company (2021)
    • 7.2.5. By Region
  • 7.3. Market Map

8. North America Ovarian Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Tumor Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Ovarian Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Ovarian Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Ovarian Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By Distribution Channel

9. Europe Ovarian Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Tumor Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Ovarian Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Ovarian Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Ovarian Cancer Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Tumor Type
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Ovarian Cancer Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Tumor Type
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Ovarian Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Tumor Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Ovarian Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Ovarian Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Ovarian Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Ovarian Cancer Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Class
        • 10.3.4.2.2. By Tumor Type
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Ovarian Cancer Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Class
        • 10.3.5.2.2. By Tumor Type
        • 10.3.5.2.3. By Distribution Channel

11. South America Ovarian Cancer Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Tumor Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Ovarian Cancer Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Tumor Type
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Ovarian Cancer Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Tumor Type
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Ovarian Cancer Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Tumor Type
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Ovarian Cancer Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Class
    • 12.2.2. By Tumor Type
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Ovarian Cancer Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Drug Class
        • 12.3.1.2.2. By Tumor Type
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Ovarian Cancer Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Drug Class
        • 12.3.2.2.2. By Tumor Type
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Ovarian Cancer Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Drug Class
        • 12.3.3.2.2. By Tumor Type
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. AstraZeneca, Plc.
  • 15.2. GlaxoSmithKline, Plc.
  • 15.3. Merck & Co.
  • 15.4. Clovis Oncology, Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Bristol-Myers Squibb Co.
  • 15.7. Eli Lilly and Company
  • 15.8. Amgen Inc.
  • 15.9. C.H. Boehringer Sohn Ko. KG
  • 15.10. Novartis AG

16. Strategic Recommendations